This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter…mehr
This highly informative and clearly written book presents the basic science and the latest data on hereditary breast and ovarian cancer (HBOC) to provide an up-to-date and holistic overview of the disease. It starts off by presenting the molecular mechanisms, genetic testing and counseling, and variants of unknown significance (VUS) to help readers understand the contemporary interpretation of the disease. Further chapters focus on the surveillance, diagnosis and treatment, including chemoprevention, risk reduction and drug development based on molecular mechanisms. It also includes a chapter on the latest findings from the HBOC database, ethical issues and the parp inhibitors, and discusses innovative thinking to manage and understand the disease. Hereditary Breast and Ovarian Cancer - Molecular Mechanism and Clinical Practice offers breast surgeons, medical oncologists, gynecological oncologists and genetic counselors a comprehensive overview of the disease. Providing insights into recent scientific findings and further avenues for investigation, it is also a thought-provoking and informative read for researchers and scholars.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Seigo Nakamura Department of Breast Surgical Oncology Showa University, School of Medicine Tokyo, Japan Daisuke Aoki Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan Yoshio Miki Department of Molecular Genetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
Inhaltsangabe
1 History, Advancements, and Future Strategies.- 2 Molecular basis of BRCA1 and BRCA2 - Homologous recombination deficiency and tissue-specific carcinogenesis.- 3 Genetic Testing.- 4 Variants of uncertain significances in hereditary breast and ovarian cancer.- 5 Genetic counseling in Hereditary Breast and Ovarian Cancer.- 6 Hereditary Breast Cancer.- 7 Hereditary Ovarian Cancer.- 8 Risk-Based Breast Cancer Screening.- 9 Chemoprevention for Breast Cancer.- 10 Chemoprevention for Ovarian Cancer.- 11 Risk-Reducing Mastectomy (RRM).- 12 Risk-reducing salpingo-oophorectomy (RRSO).- 13 Panel Testing.- 14 Germline Findings through Precision Oncology for Ovarian Cancer.- 15 Germline Findings from Genetic Testing for Breast Cancer.- 16 Hereditary Breast and Ovarian Cancer (HBOC) Database.- 17 Ethical Issues: Overview in Genomic analysis and Clinical Context.- 18 PARP Inhibitors-Mechanism of action.- 19 PARPi - Efficacy in Hereditary Breast Cancer.- 20 Efficacy of Poly ADP-Ribose Polymerase Inhibitors for Hereditary Ovarian Cancer.
1 History, Advancements, and Future Strategies.- 2 Molecular basis of BRCA1 and BRCA2 - Homologous recombination deficiency and tissue-specific carcinogenesis.- 3 Genetic Testing.- 4 Variants of uncertain significances in hereditary breast and ovarian cancer.- 5 Genetic counseling in Hereditary Breast and Ovarian Cancer.- 6 Hereditary Breast Cancer.- 7 Hereditary Ovarian Cancer.- 8 Risk-Based Breast Cancer Screening.- 9 Chemoprevention for Breast Cancer.- 10 Chemoprevention for Ovarian Cancer.- 11 Risk-Reducing Mastectomy (RRM).- 12 Risk-reducing salpingo-oophorectomy (RRSO).- 13 Panel Testing.- 14 Germline Findings through Precision Oncology for Ovarian Cancer.- 15 Germline Findings from Genetic Testing for Breast Cancer.- 16 Hereditary Breast and Ovarian Cancer (HBOC) Database.- 17 Ethical Issues: Overview in Genomic analysis and Clinical Context.- 18 PARP Inhibitors-Mechanism of action.- 19 PARPi - Efficacy in Hereditary Breast Cancer.- 20 Efficacy of Poly ADP-Ribose Polymerase Inhibitors for Hereditary Ovarian Cancer.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826